WALTHAM, Mass.–(BUSINESS WIRE)–Palleon Pharmaceuticals, a leading biotech company developing drugs that target the Siglec-Sialoglycan axis to treat cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in National Harbor, MD. The first poster will show recent preclinical data on the company’s EAGLE platform, a first-in-class modality that targets the Siglec-Sialoglycan axis for treating cancer. The Siglec-Sialoglycan axis is very difficult to target by conventional approaches because of the structural diversity of sialylated tumor glycans and the redundancy of the Siglec receptors. The EAGLE platform makes targeting possible by enzymatically removing the critical



This content is restricted to site members. If you are an existing user, please log in. New users may register too.